Date: 2012-03-06
Type of information: Grant
Company: Numab (Switzerland)
Investors: Swiss Commission for Technology and Innovation (CTI) (Switzerland)
Amount: CHF 895 000 (€ 742 604)
Funding type: grant
Planned used: The grant supports Numab’s research on antibody-based approaches for the therapy of ion channel-driven health disorders.
Others: Numab AG has announced the approval of a research grant from the Swiss Commission for Technology and Innovation (CTI). The CTI supports Numab’s research on antibody-based approaches for the therapy of ion channel-driven health disorders with a grant of CHF 895’000. Numab is conducting the research activities within this project in collaboration with the Zürich University of applied Sciences (ZHAW).
Therapeutic area:
